Literature DB >> 11334572

Combinatorial lead optimization of a neuropeptide FF antagonist.

L Prokai1, K Prokai-Tatrai, A Zharikova, X Li, J R Rocca.   

Abstract

The tripeptide Pro-Gln-Arg-NH2, derivatized at the secondary amino group of the proline residue with 5-(dimethylamino)-1-naphthalenesulfonyl (dansyl-PQR-NH2), antagonizes the central anti-opioid action of neuropeptide FF in animals after systemic administration and, therefore, is a therapeutic lead to treat opiate withdrawal. For a combinatorial optimization to improve potency, libraries focused on the possible replacement of the proline and glutamine residues of this lead compound were obtained by a solid-phase split-and-mix method using coded amino acids (excluding cysteine) as building blocks. After screening for competitive binding against a radioiodinated neuropeptide FF analogue, 5-(dimethylamino)-1-naphthalenesulfonyl-Gly-Ser-Arg-NH2 (dansyl-GSR-NH2) has emerged as one of the compounds in the library with high affinity to the NPFF receptor and even with a moderate increase compared to dansyl-PQR-NH2 in its predicted ability to penetrate the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11334572     DOI: 10.1021/jm000512o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Atypical signaling and functional desensitization response of MAS receptor to peptide ligands.

Authors:  Kalyan C Tirupula; Russell Desnoyer; Robert C Speth; Sadashiva S Karnik
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

2.  Total Synthesis and Conformational Analysis of Naturally Occurring Lipovelutibols along with Lead Optimization of Lipovelutibol D.

Authors:  Varun Pratap Singh; Anup Singh Pathania; Sonia Sharma; Fayaz Ahmed Malik; Anil Kumar; Deepika Singh; Ram A Vishwakarma
Journal:  ACS Omega       Date:  2021-02-26

3.  Role of neuropeptide FF in central cardiovascular and neuroendocrine regulation.

Authors:  Jack H Jhamandas; Valeri Goncharuk
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-07       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.